TLDR
- Q1 adjusted earnings reached $0.75 per share, surpassing Wall Street’s $0.72 projection
- Quarterly revenue totaled $13.8 billion, bolstered by robust Eliquis performance
- Year-over-year net income decreased 9% to $2.7 billion; diluted earnings per share declined 10%
- 2026 full-year outlook unchanged: adjusted EPS target of $2.80ā$3.00, revenue forecast of $59.5Bā$62.5B
- Shares climbed approximately 0.5% to roughly $26.33 during premarket activity
Pfizer delivered first-quarter results that exceeded expectations, driving shares higher by about 0.5% to $26.33 in premarket hours.
The pharmaceutical company reported adjusted profit of $0.75 per share for the quarter, topping the analyst consensus of $0.72. Quarterly sales reached $13.8 billion.
The blood thinner Eliquis, representing one of Pfizer’s most significant revenue generators, maintained its strong commercial performance. This medication continues serving as a critical pillar while legacy products demonstrate unexpected resilience.
Chief Financial Officer David Denton highlighted 22% operational sales growth stemming from recently introduced and acquired medications. This metric represents a positive trend the company aims to sustain.
Profitability metrics showed some softness, though. Net income totaled $2.7 billion, reflecting a 9% year-over-year decrease. Diluted earnings per share registered at $0.47, marking a 10% annual drop.
Annual Projections Remain Unchanged
Pfizer upheld its 2026 financial forecast, keeping the guidance initially provided in December intact. The pharmaceutical giant continues to target adjusted earnings per share between $2.80 and $3.00, with annual revenue projected at $59.5 billion to $62.5 billion.
Wall Street analysts had projected $2.96 in earnings per share and $61.4 billion in revenue, figures that fall comfortably within Pfizer’s guidance parameters.
The company also reiterated that share repurchases will not occur during 2026. This position remains firm regardless of financial performance throughout the year.
Chief Executive Officer Albert Bourla expressed optimism about the company’s trajectory. “We’re off to a strong start in 2026,” he noted, highlighting favorable Phase 3 trial outcomes and promising mid-stage clinical data.
Bourla emphasized oncology and obesity as strategic focus areas where he believes Pfizer is “positioned to lead.”
Looming Patent Expirations Present Challenge
Expiring patent protections continue representing a significant near-term headwind for Pfizer’s business. Critical intellectual property safeguards on major products, including Eliquis, face expiration within the next several years.
Pfizer has implemented strategies to mitigate this challenge. The organization has negotiated arrangements with generic drug producers to prolong exclusivity on select medications, including Vyndaqel.
Additionally, the company has pursued expansion through strategic acquisitions and internal development initiatives to strengthen its product pipeline.
Management describes the research and development pipeline as progressing across numerous therapeutic areas, with oncology and obesity programs receiving particular emphasis from leadership.
First-quarter sales increased 5% year-over-year to $14.5 billion on a reported basis, exceeding market forecasts entering the earnings release.
The combination of earnings and revenue outperformance provided shareholders with stronger results than many had anticipated.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
